Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ONXEO S.A. AC.PORT.EO-,25
No Price
Closing Price XPAR 30.04.2026:
0,16 EUR
30.04.2026 15:35
Current Prices from ONXEO S.A. AC.PORT.EO-,25
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Paris
ALVIO.PA
EUR
30.04.2026 15:35
0,16 EUR
-
Share Float & Liquidity
Free Float86,75 %
Shares Float303,31 M
Shares Outstanding349,65 M
Company Profile for ONXEO S.A. AC.PORT.EO-,25 Share
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
